Pharmacotherapy Publishing Inc
View my basket
Atypon Link logo

You have no access to this article

Possible Drug-Associated Pancreatitis after Paclitaxel-Cremophor Administration


Author(s): Kimberly M. Mills | Deborah M. Johnson | Mark Middlebrooks | Gary V. Burton
doi: 10.1592/phco.20.1.95.34653
Prev | Table of contents | Next
 
View PDF article (22 K) View references
Email this link
 What is RSS?
Trouble viewing articles as PDF?
 
  Pharmacotherapy
 
Print ISSN: 0277-0008
Volume: 20 | Issue: 1
Cover date: January 2000
Page(s): 95-97
 
 
  Keywords
 
paclitaxel, pancreatitis, intravenous cyclosporine, cremophor, CrEL
 
  Abstract

Paclitaxel, a relatively new antineoplastic agent, is associated with numerous side effects, including two reported cases of pancreatitis. Our patient also developed paclitaxel-associated pancreatitis. Several companion drugs, including steroids, diphenhydramine, histamine2 blockers, serotonin type 3 antagonists, and other chemotherapeutic agents administered with paclitaxel, must be considered as possible causes of pancreatitis. In addition, paclitaxel is a hydrophobic agent that requires a vehicle, cremophor (CrEL), for solubility. Intravenous cyclosporine also requires CrEL and has been associated with pancreatitis. In the cerulein-induced pancreatitis rat model, paclitaxel with dimethyl sulfoxide as a vehicle prevents pancreatitis, suggesting that another causal agent is responsible. Animal studies of CrEL as a single agent may be required to settle this question, but for now, awareness that paclitaxel may be associated with pancreatitis may lead to earlier treatment of this potentially fatal complication.

 
  Author(s) affiliations
 
1. Department of Internal Medicine, LSU Health Sciences Center, Shreveport, Louisiana.
2. Department of Hematology/Oncology, LSU Health Sciences Center, Shreveport, Louisiana.
3. Department of Pharmacy, LSU Health Sciences Center, Shreveport, Louisiana.
4. Department of Hematology/Oncology, LSU Health Sciences Center, Shreveport, Louisiana.
Address reprint requests to Gary V. Burton, M.D., Department of Hematology/Oncology, Feist-Weiller Cancer Center, LSU Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130.